Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Operating Costs and Expenses:
General and administrative	$ 1,154	$ 1,620
Research and development	2,418	3,370
Total Operating Costs and Expenses	3,572	4,990
Loss from Operations	(3,572)	(4,990)
Other Income:
Change in fair value of warrant liability	0	2,655
Interest income	44	9
Total Other Income	44	2,664
Net Loss	(3,528)	(2,326)
Net Loss Attributable to Non-controlling Interest	(16)	(10)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	(3,512)	(2,316)
Net Loss Attributable to Common Stockholders	$ (3,971)	$ (2,375)
Net Loss Per Share - Basic and Dilutive	$ (0.25)	$ (0.65)
Weighted average number of shares outstanding during the period - Basic and Dilutive	15,656,784	3,673,340
Series A Preferred Stock [Member]
Other Income:
Preferred Stock Dividends, Income Statement Impact	$ (61)	$ (59)
Series B Preferred Stock [Member]
Other Income:
Net Loss Attributable to Non-controlling Interest	0	0
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	0	0
Preferred Stock Dividends, Income Statement Impact	$ (398)	$ 0